TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15767470
Drug: Irbesartan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (300 mg) for 12 weeks
Study: 11272364
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy using the Galileo Centering Catheter
Study: 1660514
Drug: Human alpha-ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human alpha-ANP infusion at 0.01 micrograms/kg per min
Study: 1660514
Drug: Placebo ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ANP infusion
Study: 27842383
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 weeks
Study: 27842383
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) for 24 weeks
Study: 17709451
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) and vitamin B-12 (1.25 mg) supplementation
Study: 8733881
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of antithyroid antibodies
Study: 7159691
Drug: Chlorbutol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorbutol (oral administration)
Study: 7159691
Drug: Chlorbutol (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorbutol (second dose)
Study: 7159691
Drug: Chlorbutol (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorbutol (multiple doses)
Study: 25921544
Drug: 33 °C
Normalized name: There is no full generic drug name associated with the abbreviation "33 °C". This appears to be a temperature measurement rather than a drug name.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 °C treatment group
Study: 25921544
Drug: 36 °C
Normalized name: There is no full generic drug name associated with the abbreviation '36 °C'. This abbreviation does not refer to a drug name, but rather a temperature measurement in degrees Celsius.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 °C treatment group
Study: 22990757
Drug: Dang Gui
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dang Gui Buxue Tang (DBT) 3.0 g/day
Study: 22990757
Drug: Dang Gui
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dang Gui Buxue Tang (DBT) 6.0 g/day
Study: 22990757
Drug: Dang Gui
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dang Gui Buxue Tang (DBT) 1.5 g/day
Study: 20376999
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (2 mg/kg), epinephrine (100 microg), and fentanyl (2.5 microg/kg)
Study: 20376999
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (2 mg/kg) and epinephrine (100 microg)
Study: 8951752
Drug: Hydrogel‐coated balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel‐coated balloon catheters delivered with heparin coating (n = 33)
Study: 8951752
Drug: Hydrogel‐coated balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel‐coated balloon catheters without heparin coating (n = 26)
Study: 6177709
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IGIV) at a dose of 20 ml/kg, administered twenty-four hours post transplantation and then weekly for 10 weeks.
Study: 25085836
Drug: Finasteride and
Normalized name: finasteride and tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride and placebo treatment arms
Study: 20570122
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (10 mg/day on days 16-25 of the menstrual cycle)
Study: 18043573
Drug: Non‐reabsorbable intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐reabsorbable intradermal suture
Study: 12122096
Drug: CMF followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMF followed by tamoxifen (20 mg/day, orally for 57 months)
Study: 12122096
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (20 mg/day, orally for 60 months)
Study: 27536443
Drug: LCTZ plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCTZ plus FFNS (combination group)
Study: 27536443
Drug: LCTZ plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCTZ plus FFNS placebo (monotherapy group)
Study: 19963158
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pequi oil capsules for 14 days
Study: 15472177
Drug: Oxandrolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (20 mg/d; n = 20)
Study: 9791142
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (Zidovudine, Lamivudine, and Indinavir)
Study: 7820985
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day telmestein
Study: 3059703
Drug: pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine 50 mg b.i.d. (n = 24)
Study: 3059703
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg b.i.d. (n = 19)
Study: 3059703
Drug: pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine 50 mg b.i.d. or cimetidine 400 mg b.i.d.
Study: 26245807
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone oral supplements (2 doses of a genistein-rich soy supplement and 3 doses of mixed isoflavones)
Study: 26245807
Drug: Genistein at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein at 52.85 mg/d
Study: 26245807
Drug: Most effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Most effective soy intervention (105.23 mg total isoflavones/d)
Study: 23864314
Drug: Stimulation off/medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation off/medication off (control condition)
Study: 14736007
Drug: Renal artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal artery stent placement with medication (statins, anti-hypertensive drugs, antiplatelet therapy)
Study: 14736007
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (statins, anti-hypertensive drugs, antiplatelet therapy)
Study: 8651094
Drug: Ramipril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1.25 to 20 mg/day)
Study: 22409354
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all treatments (1,064 nm, 1,319 nm, and blended)
Study: 17035939
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein diet (VLPD) supplemented with ketoanalogs (0.35 g/kg/day)
Study: 17035939
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD, 0.60 g/kg/day)
Study: 11381492
Drug: Combination TA1
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination TA1 and IFN-alpha 2b
Study: 9815011
Drug: Alcohol (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (48 g)
Study: 779692
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide administered during 7 days
Study: 31477152
Drug: Aspirin (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (162 mg daily for 2 weeks)
Study: 31477152
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg daily for 2 weeks)
Study: 31477152
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Aspirin 162 mg and Pravastatin 40 mg daily for 2 weeks)
Study: 27049526
Drug: 25(OH)D concentrations
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentrations ≥40 ng/ml
Study: 27049526
Drug: 25(OH)D concentrations
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentrations <20 ng/ml
Study: 9505161
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (280 mg daily for 10 weeks)
Study: 7785553
Drug: Flomoxef only
Normalized name: flomoxef
DrugBank: Flomoxef (DB11935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flomoxef only for 2 or 3 days and no drugs later (Group D, n = 10)
Study: 372839
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (therapeutic serum levels of 0.7-1.1 mmol/L)
Study: 31980913
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (DC vaccination + cisplatin)
Study: 31151333
Drug: Complex Decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex Decongestive Therapy (CDT) - 10 sessions over 2 weeks
Study: 24392996
Drug: Injection-site warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection-site warming device (InsuPad)
Study: 12126907
Drug: RV3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV3 vaccine (6.5 x 10(5) fcfu)
Study: 7895551
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg lansoprazole once daily
Study: 284719
Drug: Propylthiouracil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil (both intravenous and oral administration)
Study: 25503599
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) coping skills training
Study: 25503599
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) skills use
Study: 21325105
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (500 mg vitamin C and 400 IU vitamin E daily)
Study: 19893971
Drug: Oxa-gel (OG)
Normalized name: (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxa-gel (OG)
Study: 16946177
Drug: Extended-release venlafaxine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release venlafaxine plus mirtazapine
Study: 14570856
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of the MR agonist fludrocortisone
Study: 11789203
Drug: Xiongshao capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiongshao capsule (XSC)
Study: 11789203
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment plus XSC
Study: 8887014
Drug: benfluorex (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: benfluorex (150 mg x 3 daily)
Study: 25827597
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection diclofenac sodium (75 mg)
Study: 23253958
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto extract (320 mg for the first 24 weeks, 640 mg for the next 24 weeks, and 960 mg for the last 24 weeks)
Study: 14985300
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost administered as 1 drop
Study: 8342828
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg ITMS
Study: 8342828
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg ITMS
Study: 8342828
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg ITMS
Study: 3790968
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of metoclopramide (7 mg/kg)
Study: 3790968
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of metoclopramide (7 mg/kg)
Study: 27575534
Drug: Social dancing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Social dancing classes (folk or ballroom dancing) twice weekly for 12 months (80 hours total)
Study: 24087940
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose therapy
Study: 20843575
Drug: Peg‐interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐interferon alpha‐2b plus 1000‐1200 mg of ribavirin daily (according to body weight) for 24 weeks (Std24)
Study: 20843575
Drug: Peg‐interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐interferon alpha‐2b plus 1000‐1200 mg of ribavirin daily for variable duration of 12 or 36 weeks (Var12/36)
Study: 16983910
Drug: Tongfu Xiere
Normalized name: GINGER 4.5 g in 100 mL TOPICAL LIQUID [Gongfu Head Soup Plant and extract platycypresssolution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongfu Xiere Recipe (TXR) combined with basic therapy (conventional treatment and antibiotics)
Study: 16983910
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy alone (control group)
Study: 16983910
Drug: Tongfu Xiere
Normalized name: GINGER 4.5 g in 100 mL TOPICAL LIQUID [Gongfu Head Soup Plant and extract platycypresssolution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongfu Xiere Recipe (TXR) combined with basic therapy
Study: 6495747
Drug: Post-infusion of
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-infusion of synthetic secretin + natural CCK
Study: 23290159
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 - 80 mg qd)
Study: 23290159
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 - 10 mg qd)
Study: 15766997
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement providing a recommended daily allowance of 15 vitamins and minerals
Study: 15766997
Drug: Routine iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine iron and folic acid supplements (control)
Study: 20120789
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement
Study: 12648027
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen 1 mg/kg
Study: 12648027
Drug: Rectal ketoprofen
Normalized name: ketoprofen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal ketoprofen 25 mg (dose normalized to 1 mg/kg)
Study: 10716682
Drug: PMF-100 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMF-100 (250 ml twice daily; PEG 14.6 g twice daily)
Study: 8613657
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g lactose in water
Study: 8613657
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g lactose in water
Study: 8613657
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g lactose in water
Study: 8613657
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g lactose in water
Study: 8613657
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g lactose in water
Study: 1359818
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (10 mg) inhaled 10 min before challenge with 4.5% NaCl
Study: 1359818
Drug: Vehicle inhaled
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle inhaled 10 min before challenge with 4.5% NaCl
Study: 24099659
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg) plus low-dose prednisone (5 mg twice daily)
Study: 24099659
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus low-dose prednisone (5 mg twice daily)
Study: 16043677
Drug: Topiramate (escalating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (escalating dose from 25 to 300 mg/d)
Study: 11888361
Drug: Stratified care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified care strategy (initial therapy based on clinical need, included zolmitriptan)
Study: 11888361
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care across attacks (first-line therapy with simple combination analgesic escalated to zolmitriptan if inadequate response)
Study: 11888361
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care within attacks (first-line therapy with simple combination analgesic escalated to zolmitriptan if inadequate response)
Study: 9862606
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg daily)
Study: 9862606
Drug: Imipramine (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50-300 mg daily)
Study: 7621460
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with EMP 280 mg twice a day and suramin 1 g weekly infusions for 6 weeks
Study: 7621460
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with EMP and suramin
Study: 7621460
Drug: EMP 280
Normalized name: NIACINAMIDE 1.75 g in 25 mL / ALLANTOIN 0.075 g in 25 mL TOPICAL PATCH [EMP COLLAGEN BOOST]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMP 280 mg alone
Study: 2220259
Drug: Recombinant methionyl
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant methionyl growth hormone (GH) 0.5-0.6 IU.kg-1.week-1
Study: 6353923
Drug: Cefoxitin solution
Normalized name: cefoxitin Injectable Solution
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefoxitin solution
Study: 6353923
Drug: Cephapirin solution
Normalized name: cephapirin
DrugBank: Cefapirin (DB01139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephapirin solution
Study: 26651376
Drug: Intensive Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Physical Therapy (PT) program, 12.4 ± 6.5 sessions for a total of 408 ± 261 minutes
Study: 19764973
Drug: Desmopressin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin treatment followed by alarm treatment after 3 months
Study: 19764973
Drug: Alarm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm treatment followed by desmopressin after 3 months
Study: 7737072
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (both groups)
Study: 16202531
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg S(+)‐ketamine
Study: 16202531
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg S(+)‐ketamine
Study: 9477785
Drug: Uncoated implants
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated implants
Study: 6130379
Drug: Sustained-release fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release fenfluramine
Study: 28723812
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (daily undulating periodized program)
Study: 18041081
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg AZLI administered BID for 14 days
Study: 18041081
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg AZLI administered BID for 14 days
Study: 12898882
Drug: Radiological examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiological examination after surgical treatment
Study: 9019842
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMH) in a single daily dose of 25000 U
Study: 9019842
Drug: Non-fractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fractionated heparin (NFH) in twice daily dose of 12500 U
Study: 9019842
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of low-molecular-weight heparin (LFH)
Study: 1874236
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement (160 mg daily)
Study: 20943111
Drug: VAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC therapy (10 days pre-treatment with VAC dressings)
Study: 6802937
Drug: Mannitol plus
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol plus furosemide (0.3 mg/kg)
Study: 31985629
Drug: Calf-length sequential
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf-length sequential compression devices
Study: 31985629
Drug: No sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sequential compression devices
Study: 30365588
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg SC twice weekly for 12 weeks, then 50 mg SC once weekly for an additional 12 weeks
Study: 21865366
Drug: L-T(3)
Normalized name: (T,G)-A-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T(3)
Study: 21865366
Drug: L-T(4)
Normalized name: (T,G)-A-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T(4)